Hereditary Angioedema Agents Coverage Criteria
Customize your policy alerts
Sign up for all Mass General Brigham Health Plan policy alerts
Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization for Kalbitor and other hereditary angioedema agents under the MassHealth medical benefit, including acute treatment, prophylaxis, continuation therapy, dosing, documentation, and authorization duration.
The policy added step-through requirements for Kalbitor involving Berinert or icatibant.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.